Major French university hospital contributing clinical trial sites and patient data across cardiovascular, neurological, and infectious disease research.
CHU Bordeaux is one of France's major university hospitals, providing advanced clinical care while contributing to European medical research — particularly in cardiovascular disease, neurology, and infectious disease. As a clinical site, their core value in EU projects lies in patient access, clinical trial execution, and real-world medical data collection. They bring deep expertise in stroke management, cardiac electrophysiology (especially atrial fibrillation treatment), and age-related cognitive disorders including dementia and Alzheimer's disease. Their participation spans from vaccine trials (Ebola, HIV) to interventional cardiology and regenerative medicine for brain repair.
BEAT AF (€1.5M, electroporation-based AF treatment), PRESTIGE-AF (stroke prevention in AF patients), MAP-IN-HEART (CT-guided catheter ablation), and ECSTATIC (cardiac electrical disorder imaging).
RESSTORE (stem cell therapy for stroke), PRESTIGE-AF (stroke prevention after intracerebral haemorrhage), and clinical contributions to stroke-related secondary prevention trials.
SENSE-Cog (sensory impairment and dementia in elderly), MEDIT-AGEING (meditation impact on Alzheimer's and ageing), and GERONTE (geriatric oncology with ICT tools).
Three Ebola vaccine development phases (EBOVAC1, EBOVAC2, EBOVAC3) and EHVA (European HIV Vaccine Alliance), serving as a clinical trial site.
BEAt-DKD (biomarkers for diabetic kidney disease) and ROADMAP (real-world Alzheimer's data platform with health economics component).
BEAT AF (pulsed electric field ablation, their largest-funded project at €1.5M) and MAP-IN-HEART (CT-guided ventricular tachycardia ablation) signal growing focus on cardiac intervention.
In 2014–2018, CHU Bordeaux focused on mental health, dementia, Alzheimer's disease, regenerative stem cell therapy for stroke, and infectious disease vaccine trials (Ebola, HIV). From 2019 onward, their portfolio shifted decisively toward cardiovascular intervention — atrial fibrillation treatment, catheter ablation techniques, and stroke prevention through anticoagulation management. The BEAT AF project (2021, their largest single grant at €1.5M) marks a clear commitment to becoming a key European site for advanced cardiac electrophysiology research.
CHU Bordeaux is consolidating around interventional cardiology and cardiac electrophysiology, making them an increasingly valuable clinical partner for cardiovascular device trials and AF treatment studies.
CHU Bordeaux operates almost exclusively as a supporting contributor rather than a project leader — zero coordinator roles across 16 projects, with 11 as third party and 5 as participant. This is typical for large university hospitals that provide clinical sites, patient cohorts, and medical expertise within large multi-centre consortia. Their 218 unique partners across 27 countries indicate they are widely trusted as a clinical trial site, but their third-party-heavy profile means engagement is often mediated through a lead partner rather than direct consortium membership.
With 218 unique consortium partners across 27 countries, CHU Bordeaux has an extensive pan-European clinical research network. Their connections span vaccine developers, neuroscience research groups, and cardiovascular research centres, reflecting their role as a multi-specialty hospital embedded in diverse medical research consortia.
CHU Bordeaux combines high-volume clinical infrastructure with research capabilities spanning cardiology, neurology, and infectious disease — a breadth uncommon for a single clinical partner. Their sustained involvement in Ebola vaccine development (three project phases over seven years) demonstrates reliability in long-running multi-phase trials. For consortium builders, they offer a proven French clinical site with patient access, regulatory experience, and the ability to support complex interventional trials like electroporation-based cardiac ablation.
